Filing Flows › Health Care › Black Diamond Therapeutics (BDTX)
Black Diamond Therapeutics (BDTX) earnings and revenue breakdown
Latest: Q1 2025 · 10-Q filed May 12, 2025 · Black Diamond Therapeutics (BDTX) Q1 2025 earnings results →
Q1 2025 81¢ of every $1 of revenue kept as net profit · operating margin 77.9%
Black Diamond Therapeutics made $70.0M in Q1 2025. Operating margin 77.9%, net earnings $56.5M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed May 12, 2025.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $70.0M in Q1 2025.
Operating profit was $54.5M, a 77.9% margin. Net earnings were $56.5M. The effective tax rate was 0.4%.
Operating cash flow was $53.4M, 94% of net earnings. Non-cash charges added back $87K of depreciation and $1.7M of share-based compensation. Working capital and other items used $4.9M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q1 2025 | 10-Q | May 12, 2025 | $70.0M | — | 77.9% | $56.5M | $53.4M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Black Diamond Therapeutics
We are a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of our company is built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Our MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain-penetrant to treat central nervous system (CNS) disease. Our compounds target families of oncogenic mutations in clinically validated pathways.
In its own words, from its 10-K, filed Mar 16, 2026.
Black Diamond Therapeutics against its Biological Products, (No Diagnostic Substances) peers
The largest companies of the same SEC industry, each at its latest quarter. Operating margin: 77.9% against the peers' median 40.8%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| BDTX Black Diamond Therapeutics | Q1 2025 | $70.0M | — | 77.9% |
| AMGN Amgen | Q3 2026 | $10.4B | +8% | 35.8% |
| GILD Gilead Sciences | Q3 2026 | $8.3B | +7% | 41.7% |
| BIIB Biogen | Q3 2026 | $2.8B | +11% | -0.3% |
| MRNA Moderna | Q3 2026 | $1.3B | +29% | 9.9% |
| NBIX Neurocrine Biosciences | Q3 2026 | $1.1B | +41% | 29.5% |
| EXEL Exelixis | Q3 2026 | $659M | +10% | 40.8% |
| HALO Halozyme Therapeutics | Q3 2026 | $493M | +39% | 59.8% |
| MGTX MeiraGTx Holdings | Q2 2026 | $321M | 87× | 76.0% |
Source: Black Diamond Therapeutics 10-Q on SEC EDGAR · CIK 1701541 · Biological Products, (No Diagnostic Substances)
13F: who owns BDTX and who is buying
More on BDTX
- How Black Diamond Therapeutics makes money: revenue by segment
- Black Diamond Therapeutics stock forecast, price target and fair value
- Who owns Black Diamond Therapeutics stock: holders, funds and Congress trades
- Is Black Diamond Therapeutics a takeover target? LBO and rumors
- Black Diamond Therapeutics recalls, complaints and regulation
History
Every quarter: Q1 2025 results